Esophageal Cancer Clinical Trial
Official title:
Effects of a "Walk, Eat, & Breathe" Nursing Intervention For Patients With Esophageal Cancer: A Randomized Controlled Trial
The purpose of this stratified randomized controlled trial (RCT) is to test the effects of Walk, Eat, & Breathe on preserving patients' nutritional status, functional walking capacity, pulmonary function, and emotional well-being during the CCRT and surgery course.Additionally, effects to reduce treatment-related complications and length of hospital stay for esophagectomy will be evaluated between experimental and control groups.
Esophageal cancer is a devastating disease with poor prognosis. This is largely due to its
rather insidious progression, so most patients were diagnosed with advanced cancer stage.
Patients with advanced stage therefore have to be treated with neoadjuvant chemoradiotherapy
(CCRT) to shrink the tumor and followed by a curative surgery (i.e., esophagectomy).
Patients' nutritional status, functional walking capacity, and emotional well-being are
substantially deteriorated, which often increase the incidence of postoperative pulmonary
complications, thus the risk of surgical death is greatly increased. To better support
patients with esophageal cancer, during this critical treatment course (approximate 4 months
in length), we develop a "Walk, Eat, & Breathe" nursing intervention consisting of
nutritional advice, walking exercise, and inspiratory muscle training. The purpose of this
stratified randomized controlled trial (RCT) is to test the effects of Walk, Eat, & Breathe
on preserving patients' nutritional status, functional walking capacity, pulmonary function,
and emotional well-being during the CCRT and surgery course. Additionally, effects to reduce
treatment-related complications and length of hospital stay for esophagectomy will be
evaluated between experimental and control groups.
For this three-year stratified RCT, a total of 144 consecutive patients will be enrolled to
ensure the power of study. Patients will be eligible for the study if they had histologically
documented, locally advanced tumors of the esophagus, defined as American Joint Committee on
Cancer (AJCC) stage IIB or higher, were scheduled for neoadjuvant chemoradiotherapy and
subsequent curative surgery, and had no contraindication precluding walking. After obtaining
the consent, participants will be first stratified by two important covariates [intake status
(oral intake or tube feeding) and tumor location (upper third or middle & lower third of
esophagus)] and then randomized separately into the experimental or control group, according
to computer-generated randomization tables.
Participants in the experimental group will receive "Walk, Eat, & Breathe" at initiation of
CCRT and ends before curative surgery. Participants in the control group received usual care.
Participants will undergo measurements at four points in time: before CCRT, after CCRT,
before surgery, and 1-month after surgery. Primary endpoints include nutritional status (body
weight, lean muscle mass), functional walking capacity (hand-grip strength, 6-min walking
distance), pulmonary function (forced vital capacity, forced expiratory volume in 1 second,
maximal inspiratory pressure), and emotional well-being (anxiety/depression, quality of
life). Secondary endpoints include treatment-related complications and length of hospital
stay for esophagectomy. The treatment-related complications will include
chemoradiotherapy-related toxicity (i.e., neutropenia, esophagitis), rates of interruptions
(i.e., discontinuation, reduction) in chemotherapy or radiotherapy, unplanned hospital
admission, incidence of postoperative pulmonary complications, and length of mechanical
ventilation for surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |